Announcements Trials
Browse Landscape

Phase

Phase 2 50Phase 1 15Phase NA 10Phase 3 10Phase 1/2 9Phase EARLY_PHASE1 4Phase 4 4Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 1

Interventions

Cisplatin 30Magnetic Resonance Spectroscopy 23Carboplatin 23pembrolizumab 21Paclitaxel 20Gemcitabine 19Specimen Handling 16Dexamethasone 15Radiotherapy 14Nivolumab 14Drug Therapy 14Doxorubicin 14Bevacizumab 14atezolizumab 13Oxaliplatin 13Cyclophosphamide 13Radiation 11Pemetrexed 11Cytarabine 11venetoclax 10Vincristine 10Prednisone 10Docetaxel 10Capecitabine 10Trastuzumab 9Temozolomide 8Rituximab 8Platinum 8Ipilimumab 8Fluorouracil 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Immune Checkpoint Inhibitors × 1 year × Clear all
NCT06958432 2025-08-07

Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II)

Sixth Affiliated Hospital, Sun Yat-sen University

Phase 2/3 Recruiting
430 enrolled
Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡